共 50 条
- [4] Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
- [5] The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab-Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center [J]. AMERICAN JOURNAL OF MEDICINE, 2023, 136 (01): : 96 - 99
- [8] Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection [J]. TRANSPLANTATION DIRECT, 2023, 9 (06): : E1485
- [9] Prophylactic effect of tixagevimab–cilgavimab on COVID-19 infection and death in Japanese patients with B cell lymphoma [J]. International Journal of Hematology, 2023, 118 : 303 - 305